Human IgG1 kappa, Isotype Control, a humanized monoclonal antibody, is an isotype control for human IgG1κ antibody. Human IgG1 kappa, Isotype Control has similar structures and biological characteristics to human immunoglobulin G1 (IgG1), but lacks the ability to bind specific antigens. Human IgG1 kappa, Isotype Control (10μg/ml; 2-6h) did not affect NK cell-mediated cytotoxicity against Castration-Resistant Prostate Cancer (CRPC) cells or normal prostate epithelial cells. Human IgG1 kappa, Isotype Control (10mg/kg; i.p.; once every 4 days for a total of 4 doses) did not affect the survival of C4-2 or 22Rv1 xenograft mice and showed no antitumor activity. Therefore, Human IgG1 kappa, Isotype Control are often used as negative controls in experiments to rule out false positives[1][2].
References:
[1] Yunlong Cao, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 2020 Jul 9;182(1):73-84.e16.
[2] Wang F, et al., TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. Cancer Lett. 2023 Aug 1;568:216300.
Human IgG1 kappa, Isotype Control，人源化单克隆抗体，是人IgG1κ抗体的同型对照物。Human IgG1 kappa, Isotype Control具有与人免疫球蛋白G1（IgG1）相似的结构和生物学特性，但缺乏特异性抗原结合能力。Human IgG1 kappa, Isotype Control（10μg/ml；2-6h）不影响NK细胞对去势抵抗性前列腺癌（CRPC）细胞或正常的前列腺上皮细胞的杀伤作用。Human IgG1 kappa, Isotype Control（10mg/kg；腹腔注射；每4天一次，共4次）不影响C4-2或22RV1异种移植小鼠的生存时间，也不表现出抗肿瘤活性。因此，Human IgG1 kappa, Isotype Control常用作实验的阴性对照，排除假阳性[1][2]。